Abilify Maintena: the monthly aripiprazole injection

Abilify Maintena is the once-monthly long-acting injectable form of aripiprazole, FDA-approved for schizophrenia (since 2013) and as maintenance treatment for bipolar I disorder (since 2017). It is one of the most widely used LAIs in modern outpatient psychiatry.

How aripiprazole works

Aripiprazole is unusual among antipsychotics: it is a partial agonist at the dopamine D2 receptor. That means it activates the receptor weakly when dopamine levels are low and effectively blocks the receptor when dopamine levels are high. The result, in theory, is more stable dopamine signalling — useful for treating psychosis without producing as much complete D2 blockade as standard antipsychotics. It is also a partial agonist at serotonin 5-HT1A and an antagonist at 5-HT2A.

Clinically this profile translates into less weight gain, less metabolic burden, and less hyperprolactinaemia than many other antipsychotics — though akathisia (internal restlessness) can be more prominent.

The depot formulation

Abilify Maintena uses aripiprazole monohydrate suspended in a sterile aqueous medium. It is injected into the deltoid or gluteal muscle, where it dissolves slowly over approximately 4 weeks. Steady-state blood levels are reached after several monthly injections.

Oral overlap requirement

Unlike Invega Sustenna, which uses a loading dose to skip oral overlap, Abilify Maintena requires a 14-day oral aripiprazole overlap after the first injection, per FDA labelling. The reason is that depot levels rise gradually after the first injection, and the oral medication maintains symptom control until depot levels are adequate.

After the first month, the oral overlap is no longer required — the once-monthly injection alone maintains therapeutic blood levels.

Dosing

Abilify Maintena comes in standard monthly doses. The right dose for any individual depends on their oral aripiprazole dose, response, and tolerance — and is decided by the prescriber, not by the patient or this article.

Missed-dose protocols

The FDA labelling defines specific protocols depending on how many days have passed since the last injection. Briefly, a few days late typically requires no special action; more delay may require a temporary oral overlap; very long delays may require a fresh oral aripiprazole bridge before the next depot injection.

Side effects

The side effect profile of Abilify Maintena mirrors oral aripiprazole, with some injection-related additions:

• Akathisia — internal restlessness, often the most common side effect, can be very distressing if not recognised
• Insomnia — particularly early in treatment
• Headache and mild anxiety
• Modest weight gain — typically less than olanzapine, paliperidone, or risperidone
• Hyperprolactinaemia is uncommon — aripiprazole tends to lower prolactin if anything
• Tardive dyskinesia with long-term use, though risk is generally lower than with first-generation antipsychotics

Less common

• Compulsive behaviours (gambling, shopping, eating, sexual behaviour) — a class effect of dopamine partial agonists worth knowing about
• Orthostatic hypotension
• QT prolongation (less than with several other antipsychotics)

Injection-site reactions

• Pain at the injection site for 1 to 3 days
• Mild swelling or bruising
• Rare nodules with long-term use

Who Abilify Maintena fits well

• Patients with adherence challenges who tolerate oral aripiprazole well
• Patients particularly concerned about weight gain or metabolic side effects
• Patients with hyperprolactinaemia on other antipsychotics
• Patients with stable response to oral aripiprazole who want monthly dosing

Who might want to consider alternatives

• Patients with severe, persistent akathisia on oral aripiprazole — it is unlikely to vanish on the depot
• Patients with very severe positive symptoms requiring rapid stabilisation (oral medications and other LAIs may be more flexible)
• Patients with active compulsive behaviour issues triggered by aripiprazole

How it compares to other aripiprazole LAIs

Abilify Maintena is not the only aripiprazole depot. Aristada (aripiprazole lauroxil) is a chemically related prodrug with monthly, 6-week, and 8-week dosing intervals — and a special initiation form called Aristada Initio that can shorten the oral overlap. Choice between the two LAIs comes down to dosing flexibility, the patient's preferences, and clinician familiarity.

The bigger picture

For patients who tolerate aripiprazole, an LAI version offers the metabolic-friendly profile of aripiprazole combined with the adherence advantage of monthly dosing — a useful combination, particularly in patients earlier in their illness where avoiding long-term metabolic damage is a priority.

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.